Skip to main content

29-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The KEYNOTE-355 trial

Javier Cortes discusses the KEYNOTE-355 trial findings for pembrolizumab plus chemotherapy in patients with recurrent inoperable or metastatic triple-negative breast cancer (5:36).

Read transcript

Have your say on Medicine Matters

Visit the conference hub

Image Credits